Original Report

The impact of a nurse practitioner-led symptom clinic on emergency department use in cancer patients


 

Background Emergency department (ED) use and hospitalization is distressing to cancer patients and drives up the cost of health care. A growing body of evidence demonstrates that more than half of those visits may be avoidable.

Objective To examine the impact of a nurse practitioner (NP)-led, physician-supervised, outpatient symptom management clinic on ED use.

Methods We conducted a retrospective review of ED encounters to quantify the frequency of ED use by oncology patients at a community cancer institute 6 months before (October 2012-March 2013) and after (April-September 2013) the initiation of an NP-staffed symptom management clinic.

Results The highest use of the ED and supportive clinic was among patients with advanced cancer, most commonly with lung or breast cancer, who were receiving cytotoxic chemotherapy. Uncontrolled symptoms of shortness of breath, pain, weakness, fever, nausea, vomiting, and diarrhea commonly led to ED visits. Despite instituting the NP-staffed symptom management clinic to manage those symptoms, there was a 17.9% increase in ED use. However, of the patients seen by the NP, 95% may have avoided hospitalization.

Limitations Retrospective study

Conclusions Our study identifies a high-risk population of patients who use the ED frequently. NP-led clinics could aggressively manage the symptom burden of these patients and potentially reduce ED visits as other studies have demonstrated. Although our study did not directly demonstrate this, we have identified weaknesses of care delivery in our clinic that could be optimized. In addition, we have demonstrated that the majority of patients seen for acute symptoms by an NP avoided an ED visit.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

A new sort of consultant: Advising doctors, patients on California’s aid-in-dying law
MDedge Hematology and Oncology
Cancer drugs most affordable in Australia, least in India and China
MDedge Hematology and Oncology
End-of-life aggressive cancer care continues despite recommendations
MDedge Hematology and Oncology
Web app boosts lung cancer survival
MDedge Hematology and Oncology
Adjuvant AI therapy for breast cancer: 10 years is superior to 5 years
MDedge Hematology and Oncology
Statins improve ovarian cancer survival
MDedge Hematology and Oncology
Glucocorticoids increase risk of S. aureus bacteremia
MDedge Hematology and Oncology
Symptoms linger after ‘successful’ gyn. cancer therapy
MDedge Hematology and Oncology
Racial bias linked with shorter, less-supportive appointments with black patients
MDedge Hematology and Oncology
Quality versus queasy: neurokinin 1 receptor antagonist use in moderately emetogenic chemotherapy
MDedge Hematology and Oncology